Reduce slowness stiffness and tremor
- Trial ID
- NCT05268887
- Official Title
- Acute Treatment of Parkinson's Disease With Gamma Frequency Stimulation
- Goal
- Reduce slowness stiffness and tremor
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Massachusetts Institute of Technology
- Study Type
- INTERVENTIONAL
- Enrollment
- 40 participants
- Conditions
- Parkinson Disease
- Interventions
- GENUS device (Active Settings), GENUS device (Sham settings)
Plain-Language Summary
It aims to see whether a short session of gamma-frequency brain stimulation can quickly ease motor symptoms like slowness, stiffness, or tremor in people with mid-stage Parkinson's. The approach uses MIT's GENUS device to deliver noninvasive ~40 Hz sensory stimulation that tries to entrain brain rhythms and modulate motor circuits, participants get either active or sham settings so effects can be compared, and everyone stays on their usual antiparkinsonian medicines at a stable dose so the device is tested as an add-on. They are looking for people aged 45 to 90 with idiopathic PD at Hoehn and Yahr stage 2 to 3, MoCA score ≥26, on stable Parkinson's meds for at least a month, and without seizures, migraines, dementia, certain implants, or major psychiatric or other neurological conditions.
Locations
- Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying GENUS device (Active Settings). It aims to see whether a short session of gamma-frequency brain stimulation can quickly ease motor symptoms like slowness, stiffness, or tremor in people with mid-stage Parkinson's. The approach uses MIT's GENUS device to deliver noninvasive ~40 Hz sensory stimulation that tries to entrain brain rhythms and modulate motor circuits, participants get either active or sham settings so effects can be compared, and everyone stays on their usual antiparkinsonian medicines at a stable dose so the device is tested as an add-on. They are looking for people aged 45 to 90 with idiopathic PD at Hoehn and Yahr stage 2 to 3, MoCA score ≥26, on stable Parkinson's meds for at least a month, and without seizures, migraines, dementia, certain implants, or major psychiatric or other neurological conditions.
- Who can participate?
- Participants must be between 45 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 5 years and 9 months.